[Antiplatelet therapy and anticoagulation in acute coronary syndrome: current evidence]

S de Waha1, H Thiele, G Richardt

  • 1Department of Cardiology and Angiology, Heart Center Bad Segeberg, Am Kurpark 1, 23795, Bad Segeberg, Deutschland, s-dw@gmx.net.

Herz
|August 2, 2014
PubMed

Insights

Optimal medical strategies, including potent antiplatelet and anticoagulant therapies, significantly improve outcomes for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI).

Area of Science:

  • Cardiology
  • Pharmacology

Context:

  • Acute coronary syndrome (ACS) prognosis has improved due to primary percutaneous coronary intervention (PCI).
  • Optimal medical management is crucial alongside mechanical reperfusion in ACS.
  • Antiplatelet and antithrombotic therapies are vital components of ACS patient care.

Purpose:

  • To present data and discuss current evidence on antiplatelet and anticoagulant therapies for ACS patients.
  • To highlight advancements in antiplatelet and anticoagulant treatment options.

Summary:

  • Newer, potent P2Y12 inhibitors offer advanced antiplatelet options beyond aspirin and clopidogrel.
  • Various anticoagulants are available for use before, during, and after PCI, including unfractionated heparin, low molecular weight heparins (e.g., enoxaparin), fondaparinux, and bivalirudin.
  • Glycoprotein IIb/IIIa inhibitors may be used adjunctively with anticoagulants.

Impact:

  • Improved patient outcomes in ACS through optimized pharmacological strategies.
  • Guidance on the selection and use of modern antiplatelet and anticoagulant agents in interventional cardiology.
  • Enhanced understanding of the evidence supporting current therapeutic recommendations for ACS management.

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
442
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
487
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
611
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
653